[{"data":1,"prerenderedAt":147},["ShallowReactive",2],{"drug-latanoprost":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":34,"contraindications":56,"warnings":57,"renal":65,"monitoring":66,"interactions":67,"review":68,"examples":71,"atc":77,"iran":79,"links":91,"populations":106,"usApproval":142},"latanoprost",1,{"fa":7,"en":8},"قطره لاتانوپروست","Latanoprost eye drops","sensory-organs",{"fa":11,"en":12},"آنالوگ پروستاگلاندین","Prostaglandin analogue",[14],{"name":15,"market":16},"Xalatan","US",[18,19,20],"xalatan","زالاتان","لاتانوپروست",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":29,"refs":30},"drops","eye-drops","ophthalmic","0.005% (50 mcg\u002FmL) ophthalmic solution",{"amount":5,"unit":28,"perUnit":28},"drop",[16],[31],{"source":32,"section":33},"fda-latanoprost","3",[35],{"id":36,"disease":36,"label":37,"population":40,"type":44,"unit":28,"dose":45,"refs":46,"notes":49},"glaucoma",{"fa":38,"en":39},"گلوکوم \u002F فشار بالای چشم — ۱ قطره یک بار شب","Glaucoma \u002F ocular hypertension — 1 drop once daily in the evening",{"minAge":41},{"value":42,"unit":43},18,"year","fixed",{"perDose":5,"dosesPerDay":5},[47],{"source":32,"section":48},"2",[50],{"text":51,"refs":54},{"fa":52,"en":53},"بیشتر از یک بار در روز نه؛ مصرف بیشتر اثر را کم می‌کند.","Not more than once daily; more frequent use reduces the effect.",[55],{"source":32,"section":48},[],[58],{"text":59,"refs":62},{"fa":60,"en":61},"تیره شدن دائمی رنگ عنبیه و پلک؛ رشد مژه.","Permanent darkening of iris and eyelid; eyelash growth.",[63],{"source":32,"section":64},"5",[],[],[],{"status":69,"reviewer":70,"date":70},"unverified",null,[72],{"regimen":36,"formulation":23,"input":73,"expect":76},{"ageYears":74,"weightKg":75},60,70,{"perDose":5},[78],"S01EE01",{"status":80,"forms":81,"refs":86},"registered",[82],{"code":83,"en":84,"fa":85},"01901","LATANOPROST 50MCG\u002FML OPH DROP","قطره چشمی لاتانوپروست ۵۰ میکروگرم \u002F میلی‌لیتر",[87],{"source":88,"section":89,"url":90},"darooyab-generic","G-3185\u002FLatanoprost","https:\u002F\u002Fwww.darooyab.ir\u002FG-3185\u002FLatanoprost",[92,96,100,103],{"kind":93,"url":94,"label":95},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=220360","ANDA220360",{"kind":97,"url":98,"label":99},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=2c87e99e-33d4-4060-8876-ff05557c05eb","FDA Latanoprost",{"kind":101,"url":102,"label":78},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=S01EE01",{"kind":104,"url":90,"label":105},"darooyab","Latanoprost",{"pregnancy":107,"lactation":116,"pediatric":124,"geriatric":133},{"level":108,"text":109,"quote":112,"refs":113},"caution",{"fa":110,"en":111},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women to inform drug-associated risks.",[114],{"source":32,"section":115},"8.1",{"level":108,"text":117,"quote":120,"refs":121},{"fa":118,"en":119},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk, caution should be exercised when latanoprost ophthalmic solution is administered to a nursing woman.",[122],{"source":32,"section":123},"8.2",{"level":125,"text":126,"quote":129,"refs":130},"not-established",{"fa":127,"en":128},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[131],{"source":32,"section":132},"8.4",{"level":134,"text":135,"quote":138,"refs":139},"ok",{"fa":136,"en":137},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness have been observed between elderly and younger patients.",[140],{"source":32,"section":141},"8.5",{"kind":143,"refs":144,"id":95},"ANDA",[145],{"source":32,"section":146},"SPL approval \u002F marketing category",1792092037432]